Corcept Therapeutics Incorporated provided earnings guidance for the full year of 2022. For the period, the company expects revenue to be in the range of $400 million and $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.04 USD | +2.18% |
|
+3.69% | -7.51% |
Jun. 14 | Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva... | ![]() |
Jun. 14 | Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.51% | 3.06B | |
+51.63% | 798B | |
+41.51% | 633B | |
-5.10% | 356B | |
+19.90% | 328B | |
+9.95% | 304B | |
+17.66% | 244B | |
+3.39% | 227B | |
+10.75% | 216B | |
+6.99% | 166B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Provides Earnings Guidance for the Full Year of 2022